Teva Pharmaceutical Industries (TEVA) to Release Earnings on Wednesday

Share on StockTwits

Teva Pharmaceutical Industries (NYSE:TEVA) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.55 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Shares of NYSE:TEVA opened at $7.83 on Tuesday. The company’s 50 day moving average is $8.49. The company has a market cap of $7.97 billion, a P/E ratio of 2.80, a PEG ratio of 0.82 and a beta of 1.64. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66. Teva Pharmaceutical Industries has a 12-month low of $7.46 and a 12-month high of $25.96.

A number of research analysts recently issued reports on the company. Oppenheimer set a $12.00 price objective on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Wednesday, June 12th. Wolfe Research assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, July 19th. They set a “peer perform” rating and a $9.00 price objective for the company. Royal Bank of Canada set a $19.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Friday, May 3rd. Credit Suisse Group reissued a “neutral” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, July 10th. Finally, Cantor Fitzgerald lowered their price target on Teva Pharmaceutical Industries from $16.00 to $9.00 and set a “neutral” rating on the stock in a report on Wednesday, June 12th. Six equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $14.87.

In other news, Director Sol J. Barer acquired 111,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were acquired at an average cost of $8.98 per share, with a total value of $996,780.00. Following the acquisition, the director now directly owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total value of $183,519.40. Following the sale, the vice president now directly owns 49,659 shares in the company, valued at $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Market Capitalization in the Stock Market

Earnings History for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wells Fargo & Co  Expected to Post Quarterly Sales of $20.79 Billion
Wells Fargo & Co Expected to Post Quarterly Sales of $20.79 Billion
Zacks: Brokerages Expect Wells Fargo & Co  Will Post Earnings of $1.19 Per Share
Zacks: Brokerages Expect Wells Fargo & Co Will Post Earnings of $1.19 Per Share
$0.53 EPS Expected for Virtusa Co.  This Quarter
$0.53 EPS Expected for Virtusa Co. This Quarter
Zacks: Brokerages Anticipate Virtusa Co.  Will Post Quarterly Sales of $327.20 Million
Zacks: Brokerages Anticipate Virtusa Co. Will Post Quarterly Sales of $327.20 Million
Brokerages Anticipate United Natural Foods Inc  Will Post Earnings of $0.69 Per Share
Brokerages Anticipate United Natural Foods Inc Will Post Earnings of $0.69 Per Share
United Natural Foods Inc  Expected to Post Quarterly Sales of $6.44 Billion
United Natural Foods Inc Expected to Post Quarterly Sales of $6.44 Billion


© 2006-2019 Ticker Report